Abstracts Archive - Page 13 of 2607 - ACR Meeting Abstracts

Abstract Number: 0133 • ACR Convergence 2025
Differences in cardiovascular risk factor control between primary and systemic lupus erythematosus-related antiphospholipid syndrome in a multiethnic cohort of 1003 patients with antiphospholipid syndrome: the SUrvey of cardiovascular disease Risk Factors (SURF) in SLE and APS project
Eleana Bolla¹, Anne Grete Semb², Michelle Petri³, Petros Sfikakis⁴, Bahar Artim Esen⁵, Gabriela Hernandez-Molina⁶, Eric Hachulla⁷, Haner Direskeneli⁸, George Karpouzas⁹, Marta Mosca¹⁰, Mohit Goyal¹¹, Nathalie Costedoat-Chalumeau¹², Angela Tincani¹³, Ayten Yazici¹⁴, Karoline Lerang¹⁵, Anne Troldborg¹⁶, Sofia Ajeganova¹⁷, Tatiana Popkova¹⁸, Elisabet Svenungsson¹⁹, Nikos Pantazis²⁰ and Maria Tektonidou²¹, ¹Rheumatology Unit, First Department of Propaedeutic Internal Medicine, Joint Academic Rheumatology Program, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece, ²Preventive Cardio-Rheuma clinic, Dept Rheum, Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ³Johns Hopkins University School of Medicine, Timonium, MD, ⁴NKUA - SCHOOL OF MEDICINE, Athens, Greece, ⁵Istanbul University, Istanbul, Istanbul, Turkey, ⁶Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Federal District, Mexico, ⁷University of Lille, LILLE, France, ⁸Marmara University, ISTANBUL, Turkey, ⁹Harbor-UCLA Medical Center, Torrance, CA, ¹⁰University of Pisa, Pisa, Pisa, Italy, ¹¹CARE Pain & Arthritis Centre, Udaipur, Rajasthan, India, ¹²Inserm DR Paris ⁵, Paris, France, ¹³ASST Spedali Civili-University of Brescia, Gussago, Brescia, Italy, ¹⁴Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey, ¹⁵Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ¹⁶Aarhus University Hospital, Aarhus, Denmark, ¹⁷Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden, ¹⁸V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ¹⁹Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, ²⁰Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece, ²¹National and Kapodistrian University of Athens, Athens, Greece
Background/Purpose: Cardiovascular disease (CVD) in antiphospholipid syndrome (APS) is driven by antiphospholipid antibody-mediated immunothrombotic mechanisms and traditional cardiovascular risk factors (CVRFs). Although the EULAR recommendations…
Abstract Number: 0121 • ACR Convergence 2025
The Prevalence and Clinical Significance of IgA Anticardiolipin and Anti-β2-Glycoprotein-I Antibody Isotypes in Antiphospholipid Antibody Positive Patients: Descriptive Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Registry
Emre Sahin¹, Yu (Ray) Zuo², Danieli Andrade³, Maria Tektonidou⁴, Vittorio Pengo⁵, Massimo Radin⁶, Chary López pedrera⁷, Diana Paredes-Ruiz⁸, H Michael Belmont⁹, Paul Fortin¹⁰, Denis WAHL¹¹, Ware Branch¹², Maria Gerosa¹³, Guilherme Ramires de Jesus¹⁴, Tatsuya Atsumi¹⁵, Maria Efthymiou¹⁶, Angela Tincani¹⁷, Esther Rodriguez-Almaraz¹⁸, Michelle Petri¹⁹, Ricard Cervera²⁰, Rohan Willis²¹, Katrien Devreese²², Maria Laura Bertolaccini²³, Hannah Cohen²⁴, Jason S. Knight² and Doruk Erkan¹, ¹Hospital for Special Surgery, New York, NY, ²University of Michigan, Ann Arbor, MI, ³University of Sao Paulo, São Paulo, São Paulo, Brazil, ⁴National and Kapodistrian University of Athens, Athens, Greece, ⁵Padova University Hospital, Padova, Italy, ⁶University of Turin, Turin, Turin, Italy, ⁷Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ⁸Biobizkaia Health Research Institute, Barakaldo, Spain, ⁹NYU School of Medicine, New York, NY, ¹⁰Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ¹¹University of Lorraine, Nancy, France, ¹²University of Utah Health Sciences Center, Salt Lake City, UT, ¹³University of Milan, Milano, Italy, ¹⁴Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Rio de Janeiro, Brazil, ¹⁵Hokkaido University, Sapporo, Japan, ¹⁶University College London, London, United Kingdom, ¹⁷ASST Spedali Civili-University of Brescia, Gussago, Brescia, Italy, ¹⁸Hospital Universitario ¹² de Octubre, Madrid, Spain, ¹⁹Johns Hopkins University School of Medicine, Timonium, MD, ²⁰Hospital Clinic Barcelona, Barcelona, Spain, ²¹University of Texas Medical Branch, Galveston, TX, ²²Ghent University, Gent, Belgium, ²³King's College London, London, United Kingdom, ²⁴University College London Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: The 2023 ACR/EULAR Antiphospholipid Syndrome (APS) Classification Criteria (CC) focus on IgG and IgM anticardiolipin (aCL) and anti-β2-glycoprotein-I antibodies (aβ2GPI). IgA isotypes were excluded…
Abstract Number: 0149 • ACR Convergence 2025
Effect Of Osteoporosis And Opioid Use On Mortality And Unplanned Healthcare Utilization Among Patients With Rheumatoid Arthritis
Viengneesee Thao, Molly Moore Jeffery, Nafisseh Warner and Elena myasoedova, Mayo Clinic, Rochester, MN
Background/Purpose: Patients with rheumatoid arthritis (RA) have a 2-fold increase in risk for osteoporosis compared to the general population. About 30-50% of RA patients experience…
Abstract Number: 0135 • ACR Convergence 2025
Rituximab in Antiphospholipid Syndrome: aPL Titer Decline and Clinical Outcomes
Omer Uludag¹, Soner Altın², Gamze Kemec², yasemin yalcinkaya³, Ahmet Gul³, Murat Inanc³ and Bahar Artim Esen⁴, ¹Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Istanbul, Turkey, ³Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Istanbul, Turkey, ⁴Istanbul University, Istanbul, Istanbul, Turkey
Background/Purpose: Rituximab treatment has been shown to be effective in non-thrombotic manifestations of APS and refractory catastrophic APS (CAPS). However, there are conflicting results regarding…
Abstract Number: 0130 • ACR Convergence 2025
Plasminogen activator inhibitor 1 increases thrombotic risk in Antiphospholipid syndrome
Koshy Nithin Thomas¹, Pratibha Singh², Anu Balakrishnan³, Amita Aggarwal⁴ and Able Lawrence⁵, ¹Christian Medical College, Vellore, Tamil Nadu, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ³Sanjay Gandhi Post Graduate Institute, India, Lucknow, Uttar Pradesh, India, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India, ⁵SGPGIMS, Lucknow, Lucknow, Uttar Pradesh, India
Background/Purpose: Antiphospholipid antibody syndrome (APS) is a common cause for acquired thrombophilia. The group termed ‘seronegative’ APS has not made any headway in the revised…
Abstract Number: 0028 • ACR Convergence 2025
Computational and Laboratory Identification of Risk-Driving Alleles on Juvenile Idiopathic Arthritis (JIA)-Associated Haplotypes
Adam He¹, Hannah Ainsworth², Kaiyu Jiang³, Ekaterina Khtovatkova², Yanmin Chen³, Carl Langefeld⁴, Charles G Danko¹ and James N. Jarvis⁵, ¹Cornell University Baker School of Veterinary Medicine, Ithaca, NY, ²Wake Forest University, Winston-Salem, NC, ³University of Washington School of Medicine, Seattle, WA, ⁴Wake Forest University School of Medicine, Winston Salem, NC, ⁵University of Washington Center for Indigenous Health, Seattle, WA
Background/Purpose: Multiple genomic regions are known to confer risk for JIA. However, identifying the SNPs that exert the biological effects that confer risk, and therefore…
Abstract Number: 2275 • ACR Convergence 2025
Agreement Between Two Rheumatoid Arthritis Response Measures Across b/ts DMARD Treatment Classes in a Large, Prospective Observational Study Supporting the Development and Clinical Validation of a Novel Blood-based Precision Medicine Test
Peter Taylor¹, Jason Carlson², Shirley Vu², Signe Fransen³, Diana Abdueva⁴ and Jeffrey Curtis⁵, ¹University of Oxford, Oxford, United Kingdom, ²Aqtual Inc, Hayward, CA, ³Aqtual, sf, CA, ⁴Aqtual, Hayward, CA, ⁵Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL
Background/Purpose: Contemporary pharmacological management of rheumatoid arthritis (RA) is set within a treat-to-target framework. This requires quantitative, longitudinal assessments of disease activity with a view…
Abstract Number: 0050 • ACR Convergence 2025
TL1A expression is upregulated in rheumatic diseases and anti-TL1A antibody reduces disease symptoms and pathological changes in rat collagen-induced arthritis
Preeyam Patel¹, Matthew Siegel², Emily Lewis³, David Giles³, Justin LaFountaine³, Joshua Friedman³ and Andy Spencer³, ¹Spyre Therapeutics, Waltham, ²Spyre Therapeutics, Menlo Park, CA, ³Spyre Therapeutics, Waltham, MA
Background/Purpose: The development of disease-modifying anti-rheumatic drugs (DMARDs) has reduced disease activity in patients living with rheumatic diseases. Despite this, there is continued unmet need…
Abstract Number: 0043 • ACR Convergence 2025
Single-cell and Spatial Transcriptomic Profiling of Muscle Reveals Inflammatory Mechanisms in Anti-glycyl tRNA Synthetase Syndrome
Takuya Harada¹, Hiroyuki Yamashita¹, Ami Isoda¹, Ken Kawaue¹, Mayuko Hayashi¹, Yutaro Misawa¹, Aruto Yamamoto¹, Miyu Wakatsuki¹, Yuya Akiyama¹, Setsuko Oyama¹, Kyoko Motomura¹, Hiroyuki Takahashi¹, Akiko Mitsuo², Yuichi Goto³, Eisei Noiri³ and Hiroshi Kaneko¹, ¹Division of Rheumatic Diseases, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan, ²Division of Clinical Laboratory Medicine, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan, ³National Center Biobank Network, Tokyo, Japan
Background/Purpose: We characterized the spatial distribution of immune cells and identified hub genes within activated molecular networks in key immune cell populations, based on the…
Abstract Number: 0019 • ACR Convergence 2025
Single cell characterization of the circulating immune system in Sjögren’s Syndrome
Alejandro Gómez Gómez¹, Héctor Corominas², Rosario Garcia Vicuña³, Mercedes Freire González⁴, Sheila Melchor-Díaz⁵, Paloma Vela Casasempere⁶, Paula Estrada-Alarcón⁷, Jose Luis Tandaipan⁸, Monica Fernandez Castro⁹, Sara Maria Rojas Herrera¹⁰, Marina Rodríguez López¹¹, Beatriz Paredes-Romero¹², Santiago Muñoz¹³, Marta López¹⁴, Ignacio Braña¹⁵, Gema Bonilla¹⁶, Raúl Menor Almagro¹⁷, Sara Manrique-Arija¹⁸, Mª Angeles Blazquez Cañamero¹⁹, Lilian López-Núñez²⁰, Carles Galisteo Veiga²¹, Juan José Alegre-Sancho²², Jose Rosas Gómez de Salazar²³, Jose Javier Pérez Venegas²⁴, Judit Font-Urgelles²⁵, José Andrés Román Ivorra²⁶, José Miguel Sequí-Sabater²⁷, Rafaela Ortega-Castro²⁸, Clara Moriano²⁹, Guadalupe Manzano-Canabal³⁰, Cilia Peralta-Ginés³¹, Javier Narváez³², Rafael Cáliz-Cáliz³³, Javier Martínez-Ferrin³⁴, Lara Sánchez Bilbao³⁵, Belén Serrano-Benavente³⁶, Natalia Boix- Martí³⁷, Ares Selles-Rius³⁸, Maribel Pérez³⁹, Juan Cañete⁴⁰, Núria Palau Balaña³⁸, Damiana Alvarez Errico³⁹, Yolanda Guillén⁴¹, Juan Ángel Patiño Galindo⁴¹, Antonio Julià¹, Sara Marsal Barril⁴² and Jose Luis Andreu⁴³, ¹Vall d'Hebron Hospital Research Institute, Rheumatology Research Group, Barcelona, Spain, ²Hospital de la Santa Creu i Sant Pau, Rheumatology, Barcelona, Barcelona, Spain, ³Hospital Universitario de la Princesa, Madrid, Spain, ⁴⁴ Hospital Universitario A Coruña, Rheumatology, A Coruña, La coruna, Spain, ⁵Hospital Universitario ¹² de Octubre, Rheumatology, Madrid, Madrid, ⁶Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, ⁷Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ⁸Rheumatology. Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Spain, ⁹PUERTA DE HIERRO HOSPITAL, Madrid, Spain, ¹⁰Hospital de Mérida, Rheumatology, Badajoz, Badajoz, Spain, ¹¹Complejo Hospitalario Universitario de Santiago, Rheumatology, Santiago de Compostela., Santiago de Compostela, Spain, ¹²Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, San Sebastian de los Reyes, Spain, ¹³Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, Madrid, Spain, ¹⁴Complex Hospitalari Universitari Moisés Broggi, Barcelona, Spain, ¹⁵Hospital Universitario Central de Asturias, Oviedo, Spain, ¹⁶Hospital Universitario La Paz, Rheumatology, Madrid, Madrid, Spain, ¹⁷Department of Rheumatology, Hospital de Jerez, Spain, Puerto De Santa María, Spain, ¹⁸Hospital Regional Universitario Málaga, Malaga, Spain, ¹⁹Hospital Ramon y Cajal, Madrid, Spain, ²⁰Hospital Son Llatzer, Rheumatology, Palma de Mallorca, Palma de Mallorca, Spain, ²¹Hospital Parc Taulí, Rheumatology, Sabadell, Sabadell, Spain, ²²Hospital Universitario Doctor Peset, Valencia, Spain, ²³Hospital Marina Baixa, PALMA DE MALLORCA, Spain, ²⁴Virgen Macarena University Hospital, Sevilla, Spain, Sevilla, Spain, ²⁵Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²⁶Hospital Universitari i Politècnic La Fe, Valencia, Spain, ²⁷Hospital Universitario La Fe (Valencia), Valencia, Spain, ²⁸Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ²⁹Hospital León, LEON, Castilla y Leon, Spain, ³⁰Hospital Virgen de la Concha (Zamora), Zamora, Spain, ³¹Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ³²Hospital Universitario de Bellvitge, Barcelona, Spain, ³³Hospital Universitario Virgen de las Nieves, Rheumatology, Granada, Granada, Spain, ³⁴Hospital Universitario Virgen de la Arrixaca, Rheumatology, Murcia, Murcia, Spain, ³⁵Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ³⁶Hospital Gregorio Marañon, Madrid, Spain, ³⁷Hospital Univetsitari Vall d'Hebron, Rheumatology Department, Barcelona, Spain, ³⁸Rheumatology Research Group, Vall d'Hebron University Hospital, Barcelona, Spain, ³⁹IMIDomics, Barcelona, Barcelona, Spain, ⁴⁰Rheumatology Department, Hospital Clínic and IDIBAPS, Barcelona, Spain, Barcelona, Spain, ⁴¹IMIDomics, Barcelona, Spain, ⁴²Vall Hebron Hospital Research Institute, Barcelona, Spain, ⁴³Hospital Universitario Puerta de Hierro, Majadahonda, Spain
Background/Purpose: Sjögren’s syndrome (SS) is a chronic autoimmune disease characterized by the infiltration of circulating immune cells into the salivary and lacrimal glands. The properties…
Abstract Number: 0046 • ACR Convergence 2025
Association of Genetic Variation in XIST and FTX with Susceptibility to Female-Biased Systemic Autoimmune Disease
Thomas Riley¹, Dana DiRenzo¹, Ellen Romich², Michael Levin³, Scott Damrauer³, Michael George¹, Montserrat Anguera¹, Joshua Baker¹ and Nikhil Jiwrajka¹, ¹University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Media, PA, ³University of Pennsylvania / Corporal Michael J. Crescenz VAMC, Philadelphia, PA
Background/Purpose: The mechanisms underlying female sex bias in autoimmune diseases remain unclear. Recent work has suggested that impaired maintenance of X-chromosome inactivation (XCI) in female…
Abstract Number: 0032 • ACR Convergence 2025
Protein Language Model-Guided Homology Identifies Microbial Enzymes Linked to Fibrosis-Prone IgG4-RD and Crohn’s Disease
Kumar Thurimella¹, Ahmed Mohamed², Chenhao Li³, Tommi Vatanen⁴, Daniel Graham³, Roisin Owens⁵, Sabina Leanti La Rosa⁶, Damian Plichta³, Sergio Bacallado⁵ and Ramnik Xavier⁷, ¹University of Colorado School of Medicine, Aurora, CO, ²Broad Institute, Boston, ³Broad Institute, Cambridge, MA, ⁴University of Helsinki, Helsinki, Finland, ⁵University of Cambridge, Cambridge, United Kingdom, ⁶NMBU, As, Norway, ⁷Harvard Medical School, Boston, MA
Background/Purpose: Uncharacterized microbial enzymes in metagenomics are difficult to annotate, especially in fibrosis-prone conditions like IgG4-related disease (IgG4-RD) and Crohn’s disease (CD), where microbial carbohydrate…
Abstract Number: 0002 • ACR Convergence 2025
KITE-363: An Autologous Anti-CD19/CD20 CAR-T Product for the Treatment of Autoimmune Rheumatic Diseases
Brian Kim, Christine Lowe, Francisco Flores, Jeremy Margaitis, Alessandro Calo, Stacey Valny, Anna Konecny, Eva Jaghatspanyan, Sean Yoder, Kenneth Ertel, Simone Filosto, Jodi Murakami and David Barrett, Kite, a Gilead Company, Santa Monica, CA
Background/Purpose: B-cell dysregulation is a key factor in the development and progression of autoimmune diseases, and B-cell inhibition has been a cornerstone of treatment for…
Abstract Number: 0021 • ACR Convergence 2025
DoCTIS: A Single Cell RNA-Seq Atlas of Drug Response To Targeted Therapies
Antonio Julià¹, Yolanda Guillén², Paloma Vela Casasempere³, Antonio Fernández Nebro⁴, Carlos Marras⁵, Santos Castañeda⁶, Jaime Calvo Alén⁷, Jesús Tornero Molina⁸, Juan Cañete⁹, Eugeni Domènech¹⁰, Javier Gisbert¹¹, Jose M. Carrascosa¹², Eduardo Fonseca¹³, Luis Bujanda Fernández De pierola¹⁴, Valle García Sánchez¹⁵, Britta Siegmund¹⁶, Giampiero Girolomoni¹⁷, Holger Heyn¹⁸, Laura Jiménez Gracia¹⁸, Pere Santamaria¹⁹, Edgar Angelats²⁰, Richard Myers²¹, Sergio H. Martínez Mateu², Juan Ángel Patiño Galindo², Ernest Choy²² and Sara Marsal¹, ¹Vall d'Hebron Hospital Research Institute, Rheumatology Research Group, Barcelona, Spain, ²IMIDomics, Barcelona, Spain, ³Hospital General Universitario de Alicante, Rheumatology, Alicante, Spain, ⁴Hospital Regional Universitario Carlos Haya, Rheumatology, Málaga, Spain, ⁵Hospital Universitario Virgen de la Arrixaca, Rheumatology, Murcia, Spain, ⁶Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ⁷Hospital Universitario de Araba, Rheumatology, Vitoria, Spain, ⁸Hospital Universitario de Guadalajara, Rheumatology, Guadalajara, Spain, ⁹Rheumatology Department, Hospital Clínic and IDIBAPS, Barcelona, Spain, Barcelona, Spain, ¹⁰Hospital Universitari Germans Trias i Pujol, Gastroenterology, Badalona, Spain, ¹¹Hospital Universitario La Princesa, Rheumatology, Madrid, Spain, ¹²Hospital Universitari Germans Trias i Pujol, Dermatology, Badalona, Spain, ¹³Complejo Hospitalario Universitario de A Coruña, Dermatology, A Coruña, Spain, ¹⁴Hospital Universitario de Donostia, Gastroenterology, San Sebastián, Spain, ¹⁵Hospital Universitario Reina Sofía, Gastroenterology, Córdoba, Spain, ¹⁶Charité-Universitätsmedizin Berlin, Gastroenterology, Berlin, Germany, ¹⁷University of Verona, Dermatology, Verona, Spain, ¹⁸Centre for Genomic Regulation (CNAG-CRG), Barcelona, Spain, ¹⁹Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelonoa, Spain, ²⁰Hospital Clínic-IDIBAPS, Barcelona, Spain, ²¹HudsonAlpha Institute for Biotechnology, Huntsville, AL, ²²Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, United Kingdom
Background/Purpose: Targeted therapies have revolutionized the management of immune-mediated inflammatory diseases (IMIDs), however, there is a substantial number of patients who respond poorly to a…
Abstract Number: 0105 • ACR Convergence 2025
Inflammatory Cytokines, Matrix Metalloproteinases and Bone Markers Expressions Are Modulated in the Joints in the Chronic Murine Model of Imiquimod-Induced Psoriasis
Guillaume LARID¹, Cassandre Dumonteix Moreau², Adrien JAMAI², Hanitriniaina Rabeony², Jean Claude LECRON², Elisabeth Gervais¹, Jean François JEGOU² and franck MOREL², ¹Poitiers University Hospital - Poitiers University - LITEC Laboratory UR ¹⁵⁵⁶⁰, Poitiers, France, ²Poitiers University - LITEC Laboratory UR ¹⁵⁵⁶⁰, Poitiers, France
Background/Purpose: Psoriatic disease is a systemic inflammatory condition which encompasses both cutaneous psoriasis (PsO), psoriatic arthritis (PsA) and multiple comorbidities. The chronic Imiquimod (IMQ) induced…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].